Get to know our clinical trials
Clinical trial to evaluate the safety of GEN1053 in monotherapy and in combination with an immunomodulator in patients with malignant solid tumors
THE PRIMARY OBJECTIVE OF THE DOSE ESCALATION PORTION OF THIS TRIAL IS TO DETERMINE THE HIGHEST TOLERATED AND SAFEST DOSE THAT CAN BE ADMINISTERED TO CANCER PATIENTS
Status
In recruitment
headquarters
Pamplona
Technical Summary
- Code EudraCT: 2021-006692-41
- Protocol number: GCT1053-01
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.